K2M Group (NASDAQ:KTWO) updated its FY17 earnings guidance on Monday. The company provided earnings per share guidance of -0.86 to -0.81 for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($0.85). The company issued revenue guidance of $257.5-258.1 million, compared to the consensus revenue estimate of $255.93 million.

K2M Group (KTWO) traded up $0.66 during trading on Monday, reaching $19.85. The company had a trading volume of 62,104 shares, compared to its average volume of 398,025. K2M Group has a fifty-two week low of $16.44 and a fifty-two week high of $25.99. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67. The company has a market capitalization of $855.31, a PE ratio of -20.68 and a beta of 1.34.

K2M Group (NASDAQ:KTWO) last posted its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The business had revenue of $62.65 million for the quarter, compared to the consensus estimate of $62.69 million. During the same quarter in the previous year, the business posted ($0.19) EPS. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. sell-side analysts anticipate that K2M Group will post -0.85 earnings per share for the current year.

A number of equities analysts recently commented on KTWO shares. Royal Bank of Canada reiterated a buy rating and set a $26.00 price target on shares of K2M Group in a report on Friday, September 22nd. Piper Jaffray Companies reiterated a buy rating and set a $28.00 price target on shares of K2M Group in a report on Thursday, September 28th. Zacks Investment Research upgraded K2M Group from a hold rating to a buy rating and set a $25.00 price target for the company in a report on Wednesday, October 4th. Needham & Company LLC reiterated a strong-buy rating and set a $27.00 price target (down previously from $29.00) on shares of K2M Group in a report on Monday, October 9th. They noted that the move was a valuation call. Finally, ValuEngine cut K2M Group from a hold rating to a sell rating in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $24.40.

COPYRIGHT VIOLATION WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/k2m-group-ktwo-updates-fy17-earnings-guidance/1798541.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with Analyst Ratings Network's FREE daily email newsletter.